Temporal Restriction of Cas9 Expression Improves CRISPR-Mediated Deletion Efficacy and Fidelity

Jesse A. Weber,Jonathan F. Lang,Ellie M. Carrell,Mohamad-Gabriel Alameh,Beverly L. Davidson
DOI: https://doi.org/10.1016/j.omtn.2024.102172
IF: 10.183
2024-03-13
Molecular Therapy — Nucleic Acids
Abstract:Clinical application of CRISPR/Cas9 technology for large deletions of somatic mutations is inefficient, and methods to improve utility suffer from our inability to rapidly assess mono- vs. biallelic deletions. Here we establish a model system for investigating allelic heterogeneity at the single cell level and identify indel scarring from non-simultaneous nuclease activity at gRNA cut sites as a major barrier to CRISPR-del efficacy both in vitro and in vivo . We show that non-simultaneous nuclease activity is partially prevented via restriction of CRISPR/Cas9 expression via inducible AAVs or lipid nanoparticles (LNPs). Inducible AAV-based expression of CRISPR-del machinery significantly improved mono- and bialleic deletion frequency in vivo , supporting the use of the X on cassette over traditional constituively-expessing AAV approaches. These data depicting improvements to deletions and insight into alleleic heterogeneity after CRISPR-del will inform therapeutic approaches for phenotypes that require either large mono- or biallelic deletions, such as autosomal recessive diseases or where mutant allele-specific gRNAs are not readily available, or in situations where the targeted sequence for excision is located multiple times in a genome.
medicine, research & experimental
What problem does this paper attempt to address?